Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study

<table>Study design. Relapse remitting and secondary progressive patients were randomized into low-blood-level (LBL) or high-blood-level (HBL) tacrolimus groups, in combination with Betaseron. Betaseron was administered subcutaneously every other day, while tacrolimus was given orally. Combination therapy was administered over a 38-week period.</table>

Multiple Sclerosis International

fig1

Figure 1

Figure 1: Combination Therapy of Interferon Beta-1b and Tacrolimus: A Pilot Safety Study 